HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: T600063-MCP200v1 6/8/1437    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Glossary Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kita, Y. Articles by Nishimura, S.-I. Search for Related Content PubMed PubMed Citation Articles by Kita, Y. Articles by Nishimura, S.-I. Social Bookmarking                      What's this?

Molecular & Cellular Proteomics 6:1437-1445, 2007.
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc.

---

Technology

Quantitative Glycomics of Human Whole Serum Glycoproteins Based on the Standardized Protocol for Liberating N-Glycans ^*,S

Yoko Kita^,, Yoshiaki Miura, Jun-ichi Furukawa, Mika Nakano^,, Yasuro Shinohara, Masahiro Ohno, Akio Takimoto and Shin-Ichiro Nishimura^,¶

From the Laboratory of Advanced Chemical Biology, Graduate School of Advanced Life Science, and Frontier Research Center for Post-Genome Science and Technology, Hokkaido University, Sapporo 001-0021, Japan and Discovery Research Laboratories, Shionogi & Co. Ltd., Osaka 553-0002, Japan

Global glycomics of human whole serum glycoproteins appears to be an innovative and comprehensive approach to identify surrogate non-invasive biomarkers for various diseases. Despite the fact that quantitative glycomics is premised on highly efficient and reproducible oligosaccharide liberation from human serum glycoproteins, it should be noted that there is no validated protocol for which deglycosylation efficiency is proven to be quantitative. To establish a standard procedure to evaluate N-glycan release from whole human serum glycoproteins by peptide-N-glycosidase F (PNGase F) treatment, we determined the efficiencies of major N-glycan liberation from serum glycoproteins in the presence of reducing agents, surfactants, protease treatment, or combinations of pretreatments prior to PNGase F digestion. We show that de-N-glycosylation efficiency differed significantly depending on the condition used, indicative of the importance of a standardized protocol for the accumulation and comparison of glycomics data. Maximal de-N-glycosylation was achieved when serum was subjected to reductive alkylation in the presence of 2-hydroxyl-3-sulfopropyl dodecanoate, a surfactant used for solubilizing proteins, or related analogues, followed by tryptic digestion prior to PNGase F treatment. An optimized de-N-glycosylation protocol permitted relative and absolute quantitation of up to 34 major N-glycans present in serum glycoproteins of normal subjects for the first time. Moreover PNGase F-catalyzed de-N-glycosylation of whole serum glycoproteins was characterized kinetically, allowing accurate simulation of PNGase F-catalyzed de-N-glycosylation required for clinical glycomics using human serum samples. The results of the current study may provide a firm basis to identify new diagnostic markers based on serum glycomics analysis.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Sato, Y. Ito, N. Arima, M. Baba, M. Sobel, M. Wakao, and Y. Suda High-Sensitivity Analysis of Naturally Occurring Sugar Chains, Using a Novel Fluorescent Linker Molecule J. Biochem., July 1, 2009; 146(1): 33 - 41. [Abstract] [Full Text] [PDF]

				R. Uematsu, Y. Shinohara, H. Nakagawa, M. Kurogochi, J.-i. Furukawa, Y. Miura, M. Akiyama, H. Shimizu, and S.-I. Nishimura Glycosylation Specific for Adhesion Molecules in Epidermis and Its Receptor Revealed by Glycoform-focused Reverse Genomics Mol. Cell. Proteomics, February 1, 2009; 8(2): 232 - 244. [Abstract] [Full Text] [PDF]

				L. Baudino, Y. Shinohara, F. Nimmerjahn, J.-I. Furukawa, M. Nakata, E. Martinez-Soria, F. Petry, J. V. Ravetch, S.-I. Nishimura, and S. Izui Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions J. Immunol., November 1, 2008; 181(9): 6664 - 6669. [Abstract] [Full Text] [PDF]

				L. Baudino, F. Nimmerjahn, Y. Shinohara, J.-I. Furukawa, F. Petry, J. S. Verbeek, S.-I. Nishimura, J. V. Ravetch, and S. Izui Impact of a Three Amino Acid Deletion in the CH2 Domain of Murine IgG1 on Fc-Associated Effector Functions J. Immunol., September 15, 2008; 181(6): 4107 - 4112. [Abstract] [Full Text] [PDF]

				C. Cederfur, E. Salomonsson, J. Nilsson, A. Halim, C. T Oberg, G. Larson, U. J Nilsson, and H. Leffler Different affinity of galectins for human serum glycoproteins: Galectin-3 binds many protease inhibitors and acute phase proteins Glycobiology, May 1, 2008; 18(5): 384 - 394. [Abstract] [Full Text] [PDF]

				Y. Miura, M. Hato, Y. Shinohara, H. Kuramoto, J.-i. Furukawa, M. Kurogochi, H. Shimaoka, M. Tada, K. Nakanishi, M. Ozaki, et al. BlotGlycoABCTM, an Integrated Glycoblotting Technique for Rapid and Large Scale Clinical Glycomics Mol. Cell. Proteomics, February 1, 2008; 7(2): 370 - 377. [Abstract] [Full Text] [PDF]